Drug Research
WuXi Advanced Therapies Announces Licensing Agreement with Janssen
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under this agreement, WuXi ATU will license to...
Drug Research
3 Viruses The Pharmaceutical Industry Needs To Prepare For
More than half of the known infectious diseases are getting worse due to climate change. Monkeypox is expanding, and recently, news of an outbreak of the Langya henipavirus in China also leaked. Researchers and public health officials are looking...
Drug Research
New Zealand Accelerates Alzheimers Treatment Development
Researchers from the University of Otago in New Zealand have taken advantage of a brain protein that has a strong chance of delaying or reversing the start of Alzheimer's disease. There are currently no viable treatments for Alzheimer's, according...
Drug Research
Patient Groups Rejoice As Pharma Dismisses Drug Pricing Law
The pharmaceutical lobbying group's aura of invincibility has faded. The U.S. Senate recently passed a new bill, leaving the pharmaceutical sector licking its wounds and paving the way for a significant drug pricing overhaul.
If the comprehensive climate and tax...
Drug Research
Why Children Are Better Protected From COVID-19 And More
There were a lot of mysteries surrounding COVID-19, some of which have been answered, but many more have not. Since the start of the pandemic, it has been a mystery as to why children appear to be considerably less...
Drug Research
Pharmacopoeias To Aid Vaccine Creation And Research Further
The mRNAVAC Working Party was established by the European Pharmacopoeia Commission to start developing standards of quality to support the developing area of messenger RNA (mRNA) vaccines.
The first job for the newly formed Working Party will be to produce...
Drug Research
AstraZeneca’s Enhertu wins keenly-anticipated U.S. breast cancer nod
AstraZeneca (AZN.L) and Daiichi Sankyo (4568.T) on Friday secured U.S. approval that broadens the use of their therapy Enhertu, for patients with breast cancer, and paves the way for billions in sales.
This is the first-ever U.S. Food and Drug Administration (FDA) approval for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
